Ligand Pharmaceuticals | LGND - 税前利润



金融业
股票价格
USD
资产
USD 2.19B
现金及等价物
USD 1.01B
销售成本
USD 11.31M
流动资产
USD 1.46B
流动负债
USD 46.74M
债务
USD 451.98M
EBIT
USD 56.62M
EBITDA
USD -14.3M
员工
68
EPS每股收益
USD 2.37
股本和储备
USD 967.52M
销售毛利
USD 100.41M
债务利息支出
USD 1.79M
利息收入
USD 6.66M
贷款资金
USD 446.9M
市值
USD 5.01B
净收入
USD 48.51M
营业费用
USD 55.1M
营业利润
USD 56.62M
普通股股本
USD 19.66M
PE价格收益
84.31
税前利润
USD -24.26M
销售收入
USD 83.7M
销售和管理费用
USD 29.12M
股票
USD 10.26M
贸易债权人
USD 9.41M
应收帐款人
USD 54.8M


税前利润 更改 日
Agenus USD 39.21M 49.82M 2026-03
Amgen USD 2.08B 570M 2026-03
Anika Therapeutics USD 764K 3M 2025-12
Arrowhead Research USD -178.9M 41.34M 2026-06
Baxter International USD 362M 368M 2026-06
Bristol-Myers Squibb USD 4.99B 1.75B 2026-06
Eli Lilly USD 8.85B 583.8M 2026-03
Enanta Pharmaceuticals USD -22.71M 95.08M 2024-12
Enviri Corporation USD 233.18M 21.88M 2026-03
Gilead Sciences USD -7.53B 10.11B 2026-06
GlaxoSmithKline GBP 2.68B 532M 2026-06
Glaxosmithkline GBP 2.14B 312M 2026-03
Heron Therapeutics USD -2.95M 14.54M 2025-12
Insmed USD -11.37M 150.72M 2026-06
Intrexon USD -60.48M 27.09M 2024-06
Ionis Pharmaceuticals USD -114M 21M 2026-06
Karyopharm Therapeutics USD -22.39M 17.51M 2026-03
Ligand Pharmaceuticals USD -24.26M 81.04M 2026-03
MacroGenics USD -36.77M 21.84M 2026-03
Merck USD -3.53B 6.95B 2026-03
Pacira USD 5M 4.43M 2026-03
Pfizer USD -653M 5.84B 2026-06
Rigel Pharmaceuticals USD -1.03M 7.22M 2024-06
Sangamo BioSciences USD -36.05M 12.94M 2024-06
Veracyte USD 26.52M 3.45M 2026-06